rxstat › Classes › Antiepileptics

Antiepileptics: shortage status in Canada

10 of the 15 antiepileptics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Brivaracetam (Brivlera) Partial shortage 1 of 8 reported products affected · est. return Dec 4, 2026 Carbamazepine (Tegretol) Partial shortage 2 of 20 reported products affected · est. return Nov 24, 2026 Clonazepam (Rivotril) Partial shortage 6 of 21 reported products affected Lacosamide (Vimpat) Partial shortage 5 of 35 reported products affected Levetiracetam Partial shortage 15 of 48 reported products affected · est. return Dec 18, 2026 Oxcarbazepine (Trileptal) Partial shortage 3 of 8 reported products affected Phenytoin (Dilantin) Partial shortage 1 of 6 reported products affected · est. return Dec 1, 2026 Stiripentol (Diacomit) Partial shortage 1 of 1 reported products affected Topiramate (Topamax) Partial shortage 10 of 42 reported products affected · est. return Feb 9, 2027 Valproic Acid (Epival) Partial shortage 4 of 24 reported products affected · est. return Jun 1, 2027 Eslicarbazepine (Aptiom) Discontinued 0 of 4 reported products affected Lamotrigine (Lamictal) No current shortage Perampanel (Fycompa) No current shortage Phenytoin (Dilantin-30) No current shortage Vigabatrin (Sabril) No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.